Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...
The FDA has given Roche its first regulatory approval for PI3K inhibitor Itovebi, clearing the drug as part of a triple therapy for certain types of locally advanced or metastatic breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback